Page 1177 - Clinical Immunology_ Principles and Practice ( PDFDrive )
P. 1177

CHAPTER 83  Hematopoietic Stem Cell Transplantation for Malignant Diseases             1140.e1


              MULTIPLE-CHOICE QUESTIONS

           1.  What is the objective of using a conditioning regimen for   3.  Which of the following increases the risk of relapse after an
             hematopoietic stem cell transplantation (HSCT)?        allogeneic stem cell transplantation?
              A. To reduce the bulk of malignant cells               A. Human leukocyte antigen (HLA) mismatched donor
                                                                           +
                                                                                                 6
              B. To decrease the risk of graft rejection             B. CD34  cell dose less than 2 × 10 /kg patient weight
              C. To improve the engraftment of donor hematopoietic stem    C. Presence of acute or chronic GvHD
               cells (HSCs)                                          D. Disease burden prior to stem cell transplantation
              D. All the above
                                                                  4.  Use of which strategy decreases the risk for acute and/or
           2.  What is the main mechanism of graft-versus-leukemia (GvL)   chronic GvHD?
             effect using donor lymphocyte infusion?                 A. Unrelated donor
              A. Release of cytokine mediators generated by the graft-versus-   B. Female donor for male recipient
               host disease (GvHD) reaction initiated by donor lymphocyte    C. Total body irradiation as part of the conditioning regimen
               infusion (DLI)                                        D. T-cell depletion of graft
              B. Provide CD4 and CD8T cells that recognize target antigens
               on tumor cells
              C. Enhance inhibitory receptors (killer cell immunoglobulin-
               like receptors [(KIRs]) recognized by donor natural killer
               (NK) cells
              D. Increase the T-cell receptor (TCR) repertoire diversity
   1172   1173   1174   1175   1176   1177   1178   1179   1180   1181   1182